Transformants (e.g., Recombinant Dna Or Vector Or Foreign Or Exogenous Gene Containing, Fused Bacteria, Etc.) Patents (Class 435/252.3)
  • Patent number: 11426447
    Abstract: The invention relates to a polypeptide, wherein said polypeptide comprises or consists of an EGF-like domain of a neuregulin protein. The invention more over relates to a nucleic acid encoding for said polypeptide, a gene therapy vector comprising said nucleic acid and genetically modified cells expressing said polypeptide. The invention relates to the medical use of said polypeptide, said nucleic acid, said gene therapy vector or said cell for the treatment of tumours of the nervous system, in particular for the treatment of tumours of the cranial or peripheral nerves, tumours associated with neurofibromatosis, schwannomas, neurofibromas and malignant nerve sheath tumours.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: August 30, 2022
    Inventors: Alexander Schulz, Helen Morrison
  • Patent number: 11396528
    Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: July 26, 2022
    Assignee: BGI SHENZHEN
    Inventors: Yunxia Tang, Bo Li, Yong Hou, Shuntao Luo, Ying Huang, Geng Liu, Dongli Li, Xiumei Lin
  • Patent number: 11390672
    Abstract: Administration of a monoclonal Ab (mAb) that specifically targets IL-1? is useful to treating articular and extra-articular symptoms of arthritis.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 19, 2022
    Assignee: Janssen Biotech, Inc.
    Inventor: John Simard
  • Patent number: 11365401
    Abstract: The disclosure relates to an oligosaccharyltransferase polypeptides and their use in the synthesis of glycoconjugates in bacterial cells; vaccines and immunogenic compositions comprising said glycoconjugates and their use in the prevention and/or treatment of bacterial infection. Bacterial expression system comprising said oligosaccharyltransferase polypeptides are also disclosed.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: June 21, 2022
    Assignee: London School of Hygiene and Tropical Medicine
    Inventors: Jon Cuccui, Brendan Wren
  • Patent number: 11365425
    Abstract: Provided are a resistant protein for use in herbicide dicamba, encoding gene and application thereof, the gene comprising: (a) a nucleotide sequence of an amino acid sequence as shown in SEQ ID NO: 2; or (b) a nucleotide sequence which is complementary to the nucleotide sequence as defined by (a) under stringent conditions; or (c) a nucleotide sequence as shown in SEQ ID NO: 1.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: June 21, 2022
    Inventors: Jian He, Li Yao, Xingjun Jia, Xiangting Xie, Yechun Wu, Qing Tao, Derong Ding
  • Patent number: 11357845
    Abstract: The present invention includes methods for treating and/or immunizing against Haemophilus influenzae, including nontypeable H. influenzae (NTHi). The methods comprise administering a composition comprising H. influenzae proteins OppA and/or LapB.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: June 14, 2022
    Inventors: Hao Shen, Brian Akerley
  • Patent number: 11357842
    Abstract: The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding PD-L1. In particular, the present invention relates to said attenuated strain of Salmonella for use in the treatment of cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: June 14, 2022
    Assignee: Vaximm AG
    Inventor: Heinz Lubenau
  • Patent number: 11344604
    Abstract: Disclosed herein is a method of treating or preventing renal disease in a subject suffering from Alport Syndrome, as well a method of treating or preventing chronic kidney disease. The method comprises administering to a subject in need thereof an effective amount of human apolipoprotein M.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: May 31, 2022
    Inventors: Alessia Fornoni, Sandra Merscher
  • Patent number: 11324807
    Abstract: The present invention relates to compositions comprising anakinra, buffer, and optionally at least one osmolyte and optionally further excipients. Further, the present invention relates to use of said compositions for treatment of for example ophthalmic disorders.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: May 10, 2022
    Assignee: Swedish Orphan Biovitrum AB (publ)
    Inventors: Ebba Florin-Robertsson, Jonas Fransson, Barry D. Moore
  • Patent number: 11319520
    Abstract: Provided herein are filter cake-based systems and methods for cultivating cells and cell biomass therefrom. Provided herein is a system for cultivating cells and cell biomass comprising a filter chamber comprising at least one inlet and at least one outlet, at least one filter support located within the filter chamber, and a filter cake located on the filter support, wherein the filter cake comprises at least one filter aid and a plurality of cells. Provided herein is a method for optimizing the cultivation of cells and cell biomass, comprising providing a filter support, adding at least one filter aid to the filter support, adding a plurality of cells to the filter aid, wherein the cells and the filter aid together comprise a filter cake, growing the cells into a cell biomass in the filter cake, wherein the filter cake is at least partially compressible.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: May 3, 2022
    Assignee: Upside Foods, Inc.
    Inventor: Konrad Mueller-Auffermann
  • Patent number: 11311027
    Abstract: Nutritive compositions containing an organism having attenuated or no poly(3-hydroxybutyrate) production are provided. These nutritive compositions are useful as feed, such as animal feed and feed additives for ruminants, non-ruminants and aquaculture, etc. Materials and methods for production of these organisms are provided.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: April 26, 2022
    Assignee: INV Nylon Chemicals Americas, LLC
    Inventors: Paul S. Pearlman, Hugo Federico Cueto Rojas, Gary Smith, Gregory S. Kirby
  • Patent number: 11298420
    Abstract: Disclosed are oncolytic viruses comprising chimeric human/mouse CD40 ligands. The chimeric human/mouse CD40 ligand may be MEM40. The oncolytic virus may be replication competent. The oncolytic virus may be an oncolytic herpes simplex virus. Also disclosed are methods comprising administering an oncolytic virus armed with at least one chimeric human/mouse CD40 ligand, for example MEM40, to a patient suffering from cancer.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: April 12, 2022
    Assignee: MEMGEN, LLC
    Inventor: Mark J. Cantwell
  • Patent number: 11261438
    Abstract: Described are mevalonate diphosphate decarboxylase variants having improved activity in converting 3-phosphonoxyisovalerate into isobutene. Such variants can be employed in processes for biologically producing isobutene from 3-hydroxyisovalerate or from 3-hydroxy-3-methylbutyrate into isobutene, for biologically producing isoprenol from mevalonate or from mevalonate-3-phosphate or for biologically producing 1,3-butadiene from 3-hydroxypent-4-enoate or from 3-phosphonoxypent-4-enoate. Also described is an enzyme which is characterized in that it is capable of converting 3-phosphonoxyisovalerate into isobutene with a kcat of more than 0.1 s?1.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: March 1, 2022
    Assignees: Global Bioenergies, Scientist of Fortune, S.A.
    Inventors: Sabine Mazaleyrat, Marc Delcourt, Maria Anissimova, Philippe Marliere
  • Patent number: 11254956
    Abstract: The invention relates to a host cell, preferably a Myceliophthora thermophila cell, which presents a lower expression and/or secretion of non-contributory cellulolytic enzymes, preferably where the non-contributory cellulolytic enzyme is endoglucanase 6 comprising SEQ ID NO: 2, thereby promoting the presence of contributory cellulolytic enzymes in the enzymatic cocktail synthesised by said host cell. The invention also relates to the use of said host cells and the enzymatic cocktails synthesised by said host cells for the production of fermentable sugars of biomass and a method for producing bioproducts, preferably bioethanol, comprising the use of said host cell or the composition according to the invention.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: February 22, 2022
    Inventors: Bruno Díez García, Noelia Valbuena Crespo, Francisco Reyes Sosa, Antonio Javier Moreno Pérez, Dolores Pérez Gómez, Ana Isabel Platero Gómez, Lucía Martín Pérez, Sandra Gavaldá Martín, Laura Viñas De La Cruz, Laura Sánchez Zamorano, Consolación Álvarez Núñez, María De Los Ángeles Bermúdez Alcántara, Javier Rocha Martín, Laura Ledesma García, Ricardo Arjona Antolín, Juan Luis Ramos Martín
  • Patent number: 11248120
    Abstract: The present invention provides methods for producing a silk protein spinning dope solution suitable for producing high toughness fibres, the thus produced silk protein spinning dope solution, methods for producing fibres using said silk protein spinning dope solution.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: February 15, 2022
    Assignee: Amsilk GmbH
    Inventors: Thomas Scheibel, Axel Leimer, Lin Römer, Lukas Eisoldt, Aniela Heidebrecht, Martha Geffers
  • Patent number: 11213577
    Abstract: Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: January 4, 2022
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventor: Claudia Gravekamp
  • Patent number: 11208447
    Abstract: The present invention relates inter alia to a polynucleotide or viral vector encoding a variant of BPIFB4 (Bactericidal/Permeability Increasing protein family B, member 4) protein and to their use for the treatment of pathologies involving impairment of nitric oxide signalling.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: December 28, 2021
    Assignee: ROXIANT APS
    Inventors: Annibale Alessandro Puca, Carmine Vecchione
  • Patent number: 11207375
    Abstract: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: December 28, 2021
    Assignees: Genocea Biosciences, Inc., Children's Medical Center Corporation
    Inventors: Todd Gierahn, Richard Malley
  • Patent number: 11198710
    Abstract: The invention is intended to identify glutathione-S-transferase that exhibits the activities to metabolize and detoxify an isoxazoline derivative, such as pyroxasulfone. The invention provides a method for cultivating a transgenic plant into which a nucleic acid encoding a protein (a or b) below has been introduced in the presence of isoxazoline derivatives: (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2; or (b) a protein comprising an amino acid sequence having 80% or higher identity to the amino acid sequence as shown in SEQ ID NO: 2 and having the activity of glutathione-S-transferase.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: December 14, 2021
    Inventors: Yoshitaka Tanetani, Kiyoshi Kawai
  • Patent number: 11186855
    Abstract: The purpose of the present invention is to provide an organism having an ergothioneine productivity that is capable of easily producing ergothioneine within a short period of time at a high yield, as compared with a conventional technology, and, therefore, enables ergothioneine production on an industrial scale. This purpose can be achieved by a transformed fungus into which a gene encoding enzyme (1) or genes encoding enzymes (1) and (2) have been inserted and in which the inserted gene(s) are overexpressed. (1) an enzyme catalyzing a reaction of synthesizing hercynyl cysteine sulfoxide from histidine and cysteine in the presence of S-adenosyl methionine, iron (II) and oxygen. (2) An enzyme catalyzing a reaction of synthesizing ergothioneine from hercynyl cysteine sulfoxide using pyridoxal 5?-phosphate as a coenzyme.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: November 30, 2021
    Inventors: Seiichi Hara, Keiko Kurosawa, Keiichi Ichikawa
  • Patent number: 11179476
    Abstract: The disclosure provides compositions comprising peptide-based nanofiber precursors and methods of using the same to inhibit cancerous cell growth and/or to deliver therapeutic or diagnostic agents to cells, e.g., cancerous cells. The compositions of the present technology include peptide-based nanofiber precursors as well as carrier complexes comprising a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor. Also provided herein are methods for delivering a therapeutic or diagnostic agent to a cell comprising contacting the cell with a carrier complex including a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 23, 2021
    Inventors: Shek Hang Benedict Law, Ching-Hsuan Tung, Vanessa Bellat
  • Patent number: 11174496
    Abstract: There is provided an acetogenic microbial cell which is capable of producing at least one higher alcohol from a carbon source, wherein the acetogenic microbial cell is genetically modified to comprise an increased expression relative to its wild type cell of at least one enzyme, E8, a butyryl-CoA:acetate CoA transferase (cat3). There is also provided a method and use of the cell to produce higher alcohols.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 16, 2021
    Assignee: Evonik Operations GmbH
    Inventors: Thomas Haas, Thomas Bülter, Anja Hecker
  • Patent number: 11168111
    Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: November 9, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Douglas MacDonald, Kara Louise Olson
  • Patent number: 11141454
    Abstract: Provided is an earthworm protein peptide for preparing a medicine for treating a thrombotic disease. The earthworm protein peptide is any one selected from a group consisting of Leu-Val-Thr-Leu-Gly-Asn-Glu (SEQ ID NO.: 1), Leu-Leu-Ala-Pro-Pro (SEQ ID NO: 2), Leu-Leu-Pro-Ala-Pro (SEQ ID NO: 3) and Thr-Val-Ala-Pro-Phe (SEQ ID NO: 4). The earthworm protein peptide can significantly inhibit the thrombin activity, thus achieving the anticoagulant effect. In vivo, the earthworm protein peptide has a significant inhibitory effect on carrageenan-induced rat tail thrombosis; and in vitro and in vivo studies of rats with thrombus, the earthworm protein peptide provided by the present invention shows good anticoagulant effects. The earthworm protein peptide has effects of thrombosis inhibition, thrombolysis, anticoagulation and fibrinolysis promotion, and can effectively prevent and treat thrombotic disease.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: October 12, 2021
    Inventors: Jiuxun Zhang, Xuejun Zhang, Mingzhan Tian, Xiping Zhang, Wei Wei
  • Patent number: 11136603
    Abstract: This disclosure relates to genome-scale attenuation or knockout strategies for directing carbon flux to certain carbon based building blocks within the 7-aminoheptanoic acid (7-AHA) and 6-aminohexanoic acid (6-AHA) biosynthesis pathways, for example, to achieve reduced flux to unwanted side products while achieving increased production of desired intermediates and end products. This disclosure also relates to non-naturally occurring mutant bacterial strains comprising one or more gene disruptions in aldehyde reductase and/or aldehyde dehydrogenase genes that are generated to direct carbon flux to certain carbon based building blocks. This disclosure further relates to a method for enhancing production of carbon based building blocks by generating non-naturally occurring mutant bacterial strains, culturing said mutant bacterial strains in the presence of suitable substrates or under desired growth conditions, and substantially purifying the desired end product.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: October 5, 2021
    Assignee: INV Nylon Chemicals Americas, LLC
    Inventors: Stephen Cartman, Jonathan Combe, Alexander B. Foster, Jonathan Kennedy
  • Patent number: 11118171
    Abstract: The invention discloses a recombinant Corynebacterium glutamicum for producing lysine by biofilm continuous fermentation and a construction method thereof, wherein the recombinant Corynebacterium glutamicum is constructed by overexpressing a protease gene FtsH in a Corynebacterium glutamicum; and the construction method comprises the following steps of: (1) performing PCR on a genome of the Corynebacterium glutamicum, and amplifying the FtsH gene to obtain an amplified FtsH gene segment; (2) cloning the FtsH gene segment to an overexpression plasmid to obtain a recombinant plasmid; and (3) introducing the recombinant plasmid into the Corynebacterium glutamicum, and screening to obtain the recombinant Corynebacterium glutamicum.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: September 14, 2021
    Assignee: Nanjing Tech University
    Inventors: Hanjie Ying, Dong Liu, Yong Chen, Qingguo Liu, Pingkai Ouyang, Ming Lei, Huanqing Niu, Bin Yu, Di Zhang, Yuhan Yang, Shishi Wu
  • Patent number: 11103568
    Abstract: Immunogenic composition are provided comprising PnCo and/or GlpO polypeptides identified as being preferentially expressed during the virulent phase of an infection related to streptococcal bacteria. The compositions can be used for eliciting immune response against streptococcal infections, such as against infections caused by S. pneumoniae.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: August 31, 2021
    Assignee: The Research Foundation for The State University of New York
    Inventors: Blaine Pfeifer, Charles Jones, Jonathan Lovell
  • Patent number: 11091782
    Abstract: Non-naturally occurring Zymomonas strains useful for the production of 2,3-butanediol are provided.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: August 17, 2021
    Assignee: Alliance for Sustainable Energy, LLC
    Inventors: Min Zhang, Yat-Chen Chou, Mary Ann Franden, Michael E. Himmel
  • Patent number: 11083787
    Abstract: The application describes recombinant BoHV-1 triple mutant viruses that express protective antigens of other bovine respiratory viruses associated with Bovine respiratory disease complex (BRDC).
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: August 10, 2021
    Assignee: Board of Supervisors of the Louisiana State University and Agricultural and Mechanical College
    Inventor: Shafiqul I. Chowdhury
  • Patent number: 11066465
    Abstract: Provided herein are anti-VEGF-A antibodies and antibody conjugates thereof. Some embodiments of the antibodies can be conjugated to a moiety, such as a HEMA-PC polymer. Some embodiments of the antibody conjugates can retain or enhance antibody activity. The antibody and conjugate thereof can be particularly useful for treating diabetic retinopathy. Further provided are methods for conjugation of a polymer to a protein such as an antibody, such as IgG1.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: July 20, 2021
    Inventors: Daniel Victor Perlroth, Wah Yuen To, Hong Liang
  • Patent number: 11065296
    Abstract: In various embodiments, a pharmaceutical composition comprising an effective amount of a peptide having the amino acid sequence represented by Formula (I) or an analog thereof, and a pharmaceutically tolerable excipient is described. In some embodiments, the analog of the peptide of Formula (I), comprises the peptide sequence of Formula (I) wherein one or more of the amino acids residues are modified by a) C-terminal modification; b) D-amino acid substitution; and/or c) deletion of one or more amino acid residues. A method of inhibiting the growth of a microorganism comprising contacting the microorganism in a medium with an effective amount of the peptide of Formula (I) or an analog thereof is also described, as are similar methods of treating a disease or disorder associated with microbial activity in a subject by administering an effective amount of a peptide of Formula (I) or an analog thereof and a pharmaceutically tolerable excipient to the subject.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: July 20, 2021
    Assignee: City University of Hong Kong
    Inventors: Yun Wah Lam, Doris Wai Ting Au, Hongyan Sun
  • Patent number: 11066456
    Abstract: The present invention provides TREM2 constructs. TREM2 constructs of the invention are polynucleotide sequences encoding a polypeptide, wherein the polypeptide comprises at least one TREM2 or fragment thereof and a targeting moiety and optionally comprising a signal peptide and/or a purification moiety. The present invention also provides isolated polypeptides encoded by TREM2 constructs, vectors comprising TREM2 constructs, isolated cells comprising said vectors, and methods of use thereof.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 20, 2021
    Assignee: Washington University
    Inventors: Marco Colonna, Yarning Wang, Marina Celia
  • Patent number: 11046735
    Abstract: Bioactive priming polypeptides are provided that are useful when applied to plants in agricultural formulations. Methods of using the formulations containing the bioactive priming polypeptides are also provided which are applied exogenously to the surface of a plant or a plant cell membrane or endogenously to the interior of a plant or to a plant cell. The bioactive priming polypeptides when applied to a plant, a plant part, or a plant growth medium or a rhizosphere in an area surrounding the plant or the plant part increase growth, yield, health, longevity, productivity, and/or vigor of a plant or a plant part and/or decrease abiotic stress in the plant or the plant part and/or protect the plant or the plant part from disease, insects and/or nematodes, and/or increase the innate immune response of the plant or the plant part and/or change plant architecture.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: June 29, 2021
    Assignee: Spogen Biotech Inc.
    Inventors: Brian Thompson, Michelle Leslie
  • Patent number: 11046936
    Abstract: The present application provides engineered polypeptides having imine or oxime reductase activity, polynucleotides encoding the engineered polypeptides, host cells capable of expressing the engineered polypeptides, and methods of using these engineered polypeptides with a range of ketone amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: June 29, 2021
    Assignee: Codexis, Inc.
    Inventors: Margie Tabuga Borra-Garske, Oscar Alvizo, Melissa Ann Mayo, Stephan Jenne, Auric Anthony Sowell-Kantz, Carmela Molinaro
  • Patent number: 11041003
    Abstract: The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: June 22, 2021
    Assignee: The Texas A&M University System
    Inventors: Magnus Hook, Ya-Ping Ko, Emanuel Smeds, Vannakambadi K. Ganesh
  • Patent number: 11040086
    Abstract: An active peptide for enhancing the phagocytic functions of retinal pigment epithelium and a use thereof, which belongs to the technical field of preparing drugs for treating retinal neurodegenerative diseases, are described. The amino acid sequence of the active peptide for enhancing the phagocytic functions of retinal pigment epithelium described in the disclosure was as shown in SEQ ID NO.1. The active peptide of the present invention has biological characteristics similar to those of Gas6 full-length proteins, with an effect of enhancing the phagocytic functions of retinal pigment epithelium.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: June 22, 2021
    Assignee: Beijing Tongren Hospital, Capital Medical University
    Inventors: Jingxue Zhang, Shen Wu, Ningli Wang
  • Patent number: 11035011
    Abstract: A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: June 15, 2021
    Inventor: Luc Montagnier
  • Patent number: 11028144
    Abstract: A soluble polypeptide comprising a modified glycoprotein V (GPV) lacking a functional transmembrane domain for use in the treatment or prevention of a thrombotic disease in a subject, said treatment or prevention comprising administering to the subject an effective amount of said soluble polypeptide.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: June 8, 2021
    Inventors: Bernhard Nieswandt, Sarah Beck, David Stegner
  • Patent number: 11027004
    Abstract: This invention relates to outer membrane vesicles (OMVs) from Gram-negative bacteria. The vesicles comprise heterologous proteins or immunogenic fragments thereof expressed as lipoproteins in their membrane. The OMVs of the invention are capable of eliciting an immune response to the heterologous protein or to a fragment thereof when administered to a mammal. Other aspects of the invention relate to methods of preparing the OMVs and immunogenic compositions containing the same.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: June 8, 2021
    Assignee: BIOMVIS SRL
    Inventors: Guido Grandi, Laura Fantappie', Carmela Irene
  • Patent number: 11008534
    Abstract: A bacteria referred to here as Bacillus subtilis 6A-1 is provided, compositions thereof and processes for use of the bacteria, spores, cells, extracts and enzymes. The compositions which comprise the bacteria, spores, cells, extracts and/or enzymes are capable of degrading polysaccharides. Such compositions are capable of degrading cellulose, including plant-produced cellulose, microcrystalline cellulose and carboxymethyl cellulose. The bacteria produces at least two cellulose-degrading protein fractions. Cellulose degrading activity continues across pH2 to pH13.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: May 18, 2021
    Assignee: AGRI-KING, Inc.
    Inventors: Gbenga Ayangbile, Mary Grzemski, James F. Tobey, Jr., David Spangler, Lucas Krueger
  • Patent number: 11002746
    Abstract: Disclosed is a blood analyzer that includes: a sample preparation unit configured to mix a blood specimen and a fluorescent dye for staining nucleic acid to prepare a measurement sample; a light receiver configured to receive fluorescence and scattered light that are generated by light being applied to the measurement sample prepared by the sample preparation unit; and a controller programmed to determine whether or not infection with Plasmodium has occurred, on the basis of a value representing variation of a distribution of first particles in a range where single-ring form of red blood cells appear, the range where single-ring form of red blood cells appear being identified according to fluorescence intensities and scattered light intensities obtained by processing of signals from the light receiver.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: May 11, 2021
    Inventors: Yuhgi Suzuki, Takuma Watanabe
  • Patent number: 10995322
    Abstract: Genetically modified isopropylmalate synthases, processes for preparing a C7-C11 2-ketoacids utilizing genetically modified isopropylmalate synthases, and microbial organisms including genetically modified isopropylmalate synthases are described. The genetically modified isopropylmalate synthases, processes for preparing a C7-C11 2-ketoacids, and microbial organisms including genetically modified isopropylmalate synthases can be particularly useful for producing corresponding Cn_1 aldehydes, alcohols, carboxylic acids, and Cn_2 alkanes both in vivo and in vitro.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: May 4, 2021
    Assignee: Dow Global Technologies LLC
    Inventors: Paresh C. Sanghani, Sarah Delaplane
  • Patent number: 10988745
    Abstract: The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: April 27, 2021
    Inventors: James Arthur Posada, Chris Gabel
  • Patent number: 10988599
    Abstract: This invention relates to the field of producing bioplastics. Specifically, it relates to a method of producing all key ingredients of bioplastic making from pumpkins and making of bioplastic with these ingredients. More specifically, glycerin and other chemicals are extracted from pumpkin seed oil and mixed with starches that in the pumpkin flesh and then reinforced with pumpkin fibers to make bioplastic. The bioplastic produced with the method as disclosed in this invention possess superior properties in tensile strength and biodegradability compared to bioplastic made with petroleum derived glycerin.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: April 27, 2021
    Inventor: Kaien Yang
  • Patent number: 10980893
    Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: April 20, 2021
    Inventors: Alex Powlesland, Maurits Kleijnen, Meidai Sun
  • Patent number: 10975122
    Abstract: The present invention relates to a peptide comprising an epitope within the macrophage scavenger receptor B-I, a method of using the same, a nucleic acid encoding the same and an antibody that binds to the epitope.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: April 13, 2021
    Inventors: Nathan Karin, Gizi Wildbaum
  • Patent number: 10960049
    Abstract: The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: March 30, 2021
    Assignee: Yale University
    Inventors: Demetrios Braddock, Ronald Albright
  • Patent number: 10961297
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: March 30, 2021
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • Patent number: 10947570
    Abstract: Disclosed are methods for regulating biosynthesis of at least one of pimelic acid, 7-aminoheptanoic acid, 7-hydroxyheptanoic acid, heptamethylenediamine, 7-aminoheptanoland 1,7-heptanediol (C7 building blocks) using a pathway having a pimeloyl-ACP intermediate, the method including the step of downregulating the activity of BioF. Also disclosed are recombinant hosts by fermentation in which the above methods are performed. Further disclosed are recombinant hosts for producing pimeloyl-ACP, the recombinant host including a deletion of a bioF gene.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: March 16, 2021
    Assignee: INV Nylon Chemicals Americas, LLC
    Inventors: Alexander Brett Foster, Stephen Thomas Cartman, Jonathan Kennedy
  • Patent number: RE48805
    Abstract: The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase (AAD) fusion protein for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, binds to human serum albumin (HSA) or animal serum albumin and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD fusion protein in the present invention are about 20 and about 19 U/mg (at physiological pH 7.4), respectively. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis. The AAD fusion protein can also be used as a component for detection and quantitative analysis of arginine in a testing kit for various samples including blood, food and analytical samples.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: November 2, 2021
    Assignee: Vision Global Holdings Ltd.
    Inventors: Bing Lou Wong, Norman Fung Man Wai, Sui Yi Kwok, Yun Chung Leung